ORIC PHARMACEUTICALS INC (ORIC)
US68622P1093 - Common Stock
ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ORIC Pharmaceuticals (NASDAQ:ORIC) just reported results for the first quarter ...
ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024
ORIC stock results show that ORIC Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations;...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused...
Oric Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ORIC
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical...
Oric Pharmaceuticals Enters Oversold Territory (ORIC)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2024 (the “Grant Date”), ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology...
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for...
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology...
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company...
First Week of March 15th Options Trading For Oric Pharmaceuticals (ORIC)
Cantor starts ORIC at overweight, cites potential of ORIC-114 (NASDAQ:ORIC)
Cantor Fitzgerald has initiated coverage of ORIC Pharmaceuticals (ORIC) with an overweight rating, citing the potential of its oncology drug ORIC-114.
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused...
Commit To Buy Oric Pharmaceuticals At $10, Earn 25.8% Annualized Using Options
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company...
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company...
ORIC Pharma files to sell 12.5M shares for holders (NASDAQ:ORIC)
The selling stockholders of ORIC Pharma (NASDAQ:ORIC) plan to offer and sell up to 12.5 million shares of common stock, the company disclosed in an SEC...
ORIC Pharmaceuticals stock rises after it announces $125M private placement (NASDAQ:ORIC)
ORIC Pharmaceuticals announced a private placement financing, selling ~12.5 million shares at $10 each, expecting to raise $125 million for funding their...
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners,...